Apararenone

Apararenone
	Antimineralocorticoid
Identifiers
	IUPAC name N-[4-(4-fluorophenyl)-2,2-dimethyl-3-oxo-1,4-benzoxazin-7-yl]methanesulfonamide;
JSmol)	Interactive image;
	SMILES CC1(C(=O)N(C2=C(O1)C=C(C=C2)NS(=O)(=O)C)C3=CC=C(C=C3)F)C;
	InChI InChI=1S/C17H17FN2O4S/c1-17(2)16(21)20(13-7-4-11(18)5-8-13)14-9-6-12(10-15(14)24-17)19-25(3,22)23/h4-10,19H,1-3H3; Key:AZNHWXAFPBYFGH-UHFFFAOYSA-N;

Apararenone (

non-alcoholic steatohepatitis.^[1]^[2]^[3] It was also previously being developed for the treatment of hypertension, but development was discontinued for this indication.^[1] Apararenone acts as a highly selective antagonist of the mineralocorticoid receptor (K_i < 50 nM), the receptor for aldosterone.^[1]^[2]^[3] As of 2017, it is in phase II clinical trials.^[1]

References

antimineralocorticoids (H02)
Mineralocorticoids	Desoxycortone (desoxycorticosterone) Desoxycortone esters Hydrocortisone (cortisol) Hydrocortisone esters Fludrocortisone Fludrocortisone acetate Methylprednisolone Methylprednisolone esters Prednisolone Prednisolone esters Prednisone Prednisone esters
Antimineralocorticoids	Steroidal: Canrenoate potassium (potassium canrenoate) Canrenone Drospirenone Dydrogesterone Eplerenone Gestodene Medrogestone Progesterone Spironolactone Trimegestone Nonsteroidal: Amlodipine Apararenone^§ Benidipine Esaxerenone^† Felodipine Finerenone Nifedipine Nimodipine Nitrendipine
Synthesis modifiers	Acetoxolone Aminoglutethimide Carbenoxolone Enoxolone Ketoconazole Metyrapone Mitotane Trilostane
^#WHO-EM ^‡Withdrawn from market Clinical trials: ^†Phase III ^§Never to phase III See also Mineralocorticoid receptor modulators Glucocorticoids and antiglucocorticoids List of corticosteroids